Treatment Clinical Trials for Malignant Mesothelioma

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Clinical trials are research studies that involve people. The clinical trials on this list are for malignant mesothelioma treatment. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-25 of 38
1 2 Next >

  • Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients with Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin

    This phase I / II trial studies the side effects and the best dose of methoxyamine when given together with cisplatin and pemetrexed disodium and to see how well it works in treating patients with solid tumors or mesothelioma that have spread to other places in the body and usually cannot be cured or controlled with standard treatment (advanced), or mesothelioma that does not respond to pemetrexed disodium and cisplatin or carboplatin (refractory). Methoxyamine may shrink the tumor and may also help cisplatin and pemetrexed disodium work better by making tumor cells more sensitive to the drugs. Drugs used in chemotherapy, such as cisplatin and pemetrexed disodium, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving methoxyamine together with cisplatin and pemetrexed disodium may be a better treatment for solid tumors or mesothelioma.
    Location: 13 locations

  • Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab in Refractory Cancer

    The purpose of this study is to evaluate the safety of enoblituzumab (MGA271) in combination with Keytruda (pembrolizumab) when given to patients with B7-H3-expressing melanoma, squamous cell carcinoma of the head and neck (SCCHN), non small cell lung cancer (NSCLC), Urothelial Cancer and other B7-H3 expressing cancers. The study will also evaluate what is the highest dose of enoblituzumab that can be given safely when given with pembrolizumab. Assessments will also be done to see how the drug acts in the body (pharmacokinetics (PK), pharmacodynamics) and to evaluate potential anti-tumor activity of MGA271 in combination with pembrolizumab.
    Location: 10 locations

  • Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma

    Patients with pleural mesothelioma that can not be surgically removed will receive durvalumab, in combination with standard chemotherapy of pemetrexed and cisplatin as first-line treatment. Durvalumab is a type of drug called a monoclonal antibody (a type of protein). Laboratory tests show that it works by allowing the immune system to detect your cancer and reactivates the immune response. This may help to slow down the growth of cancer or may cause cancer cells to die. The purpose of this study is to see whether adding durvalumab to standard chemotherapy will improve overall survival (OS).
    Location: 9 locations

  • Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.

    This study is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and anti-tumor activity of LAG525 as a single agent and in combination with PDR001 to adult patients with solid tumors. The study consists of a dose escalation phase (I) to determine the maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D) for LAG525 as a single agent and in combination with PDR001, and a dose expansion phase (II) which will characterize treatment of LAG525 as a single agent and in combination with PDR001 at the MTD or RP2D.
    Location: 6 locations

  • Mesothelin-Specific Genetically Engineered Lymphocytes with or without Cyclophosphamide in Treating Patients with Malignant Pleural Disease

    This phase I trial studies the side effects and best dose of mesothelin-specific chimeric antigen receptor-engineered peripheral blood lymphocytes with or without cyclophosphamide in treating patients with a malignant disease found in the thin layer of tissue that covers the lungs and lines the interior wall of the chest cavity (pleura), including malignant pleural mesothelioma, or previously treated non-small cell lung cancer or breast cancer that has spread to the pleura. Placing a gene that has been created in the laboratory into white blood cells (lymphocytes) may help the body build an immune response to kill tumor cells expressing the protein mesothelin. Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving mesothelin-specific chimeric antigen receptor-engineered peripheral blood lymphocytes with or without cyclophosphamide may be a better treatment for malignant pleural disease.
    Location: 6 locations

  • Surgery, Chemotherapy, and Intensity Modulated Radiation Therapy in Treating Patients with Stage I-III Pleural Mesothelioma

    This phase II trial studies the side effects of surgery, chemotherapy, and intensity modulated radiation therapy in treating patients with stage I-III pleural mesothelioma. Drugs used in chemotherapy, such as pemetrexed disodium, cisplatin, and carboplatin, work in different ways to stop the growth of cancer, either by killing the cancer cells, by stopping them from dividing, or by stopping them from spreading. Intensity modulated radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Giving chemotherapy before radiation therapy may help kill more tumor cells after surgery.
    Location: 6 locations

  • Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients

    The purpose of this study is to test the effectiveness and tolerability of the combination of Nivolumab and Ipilimumab compared to Pemetrexed and Cisplatin or Carboplatin in patients with unresectable pleural mesothelioma.
    Location: 5 locations

  • Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in Refractory Cancer

    The purpose of this study is to evaluate the safety of enoblituzumab (MGA271) in combination with Yervoy (ipilimumab) when given to patients with B7-H3-expressing melanoma, squamous cell carcinoma of the head and neck (SCCHN), non small cell lung cancer (NSCLC) and other B7-H3 expressing cancers. The study will also evaluate what is the best dose of enoblituzumab to use when given with ipilimumab. Assessments will also be done to see how the drug acts in the body (pharmacokinetics (PK), pharmacodynamics) and to evaluate potential anti-tumor activity of enoblituzumab in combination with ipilimumab.
    Location: 6 locations

  • Evaluation of CRS-207 With Pembrolizumab in Previously Treated MPM

    The purpose of this study is to evaluate whether CRS-207 with pembrolizumab is safe and effective in adults with MPM who have failed prior anti-cancer therapy.
    Location: 3 locations

  • Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole

    Characterize the safety, tolerability, ECG effects, pharmacokinetics and immunogenicity of anetumab ravtansine given as single agent and after inhibition of CYP3A4 and P-gp by concomitant administration of itraconazole in subjects with mesothelin-expressing advanced solid cancers
    Location: 3 locations

  • Ph 2 / 3 Study in Subjects With MPM w / Low ASS 1 Expression to Assess ADI-PEG 20 With Pemetrexed and Cisplatin

    This is a study of ADI-PEG 20 (pegylated arginine deiminase), an arginine degrading enzyme versus placebo in patients with malignant pleural mesothelioma with low argininosuccinate synthetase 1 expression. Malignant pleural mesothelioma have been found to require arginine, an amino acid. Thus the hypothesis is that by restricting arginine with ADI-PEG 20, the malignant pleural mesothelioma cells will starve and die.
    Location: 4 locations

  • Phase Ib Study of Anetumab Ravtansine in Combination With Pemetrexed and Cisplatin in Mesothelin-expressing Solid Tumors

    Determine the safety, tolerability and maximum tolerated dose of anetumab ravtansine (BAY 94-9343) in combination with pemetrexed 500 mg / m2 and cisplatin 75 mg / m2 in subjects with mesothelin-expressing predominantly epithelial mesothelioma or nonsquamous non-small-cell lung cancer.
    Location: 3 locations

  • Nintedanib in Treating Patients with Malignant Pleural Mesothelioma That Is Recurrent or Cannot Be Removed by Surgery

    This phase II trial studies how well nintedanib works in treating patients with malignant pleural mesothelioma that has come back (recurrent) or cannot be removed by surgery. Nintedanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: 3 locations

  • Tremelimumab and Durvalumab in Treating Patients with Malignant Pleural Mesothelioma That Cannot be Removed by Surgery

    This phase II clinical trial studies how well tremelimumab and durvalumab work in treating patients with malignant pleural mesothelioma that cannot be removed by surgery. Monoclonal antibodies such as tremelimumab and durvalumab, may interfere with the ability of tumor cells to grown and spread. Giving tremelimumab with durvalumab may be a better way to treat malignant pleural mesothelioma.
    Location: 2 locations

  • Chemotherapy With or Without Porfimer Sodium-Based Photodynamic Therapy During Surgery in Treating Patients With Malignant Pleural Mesothelioma

    This randomized phase II trial studies how well chemotherapy with or without porfimer sodium-based photodynamic therapy during surgery works in treating patients with malignant pleural mesothelioma. Drugs used in chemotherapy, such as pemetrexed disodium, work in different ways to stop the growth of cancer, either by killing the cancer cells, by stopping them from dividing, or by stopping them from spreading. Photodynamic therapy uses a drug, such as porfimer sodium, that becomes active when it is exposed to a certain kind of light. When the drug is active, tumor cells are killed. It is not yet known whether chemotherapy is more effective with or without porfimer sodium-based photodynamic therapy during surgery in treating patients with malignant pleural mesothelioma.
    Location: 2 locations

  • Surgery With or Without Intraoperative Heated Cisplatin and Sodium Thiosulfate Followed by Pemetrexed Disodium and Cisplatin in Treating Patients With Malignant Pleural Mesothelioma

    RATIONALE: Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of cancer, either by killing the cancer cells or by stopping them from dividing. Heating a chemotherapy solution and infusing it directly into the abdomen may kill more tumor cells. Chemoprotective drugs, such as sodium thiosulfate, may protect normal cells from the side effects of chemotherapy. Pemetrexed disodium may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Chemotherapy, given before and after surgery, followed by pemetrexed disodium may be effective treatment for malignant pleural mesothelioma. PURPOSE: This randomized phase II trial is studying how well surgery with or without intraoperative heated cisplatin and sodium thiosulfate followed by pemetrexed disodium and cisplatin works in treating patients with malignant pleural mesothelioma.
    Location: 2 locations

  • Atezolizumab and Bevacizumab in Treating Patients with Rare Solid Tumors

    This phase II trial studies how well atezolizumab and bevacizumab work in treating patients with rare solid tumors. Monoclonal antibodies, such as atezolizumab and bevacizumab block tumor growth in different ways by targeting certain cells.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Brentuximab Vedotin in Treating Patients with CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery

    This phase II trial studies how well brentuximab vedotin works in treating patients with CD30+ malignant mesothelioma that cannot be removed by surgery. Monoclonal antibodies, such as brentuximab vedotin, may interfere with the ability of tumor cells to grow and spread.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Pembrolizumab after Radiation Therapy in Treating Patients with Pleural Malignant Mesothelioma

    This phase I trial studies the side effects and best way to give pembrolizumab after radiation therapy in treating patients with pleural malignant mesothelioma. Radiation therapy uses high energy radiation to kill tumor cells and shrink tumors. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Giving pembrolizumab after radiation therapy may kill more tumor cells.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Plicamycin in Treating Patients with Primary Thoracic Malignancies or Carcinomas, Sarcomas, or Germ Cell Tumors with Pleuropulmonary Metastases

    This phase I / II trial studies the best dose and side effects of plicamycin and how well it works in treating patients with primary thoracic malignancies or carcinomas, sarcomas, or germ cell tumors that have spread to organs in the chest. Plicamycin may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: National Institutes of Health Clinical Center, Bethesda, Maryland

  • LMB-100 with or without Nab-Paclitaxel in Treating Patients with Mesothelin Positive Solid Tumors or Recurrent, Metastatic, and / or Locally Advanced Pancreatic Cancer

    This phase I / II trial studies the side effects and best dose of anti-mesothelin-pseudomonas exotoxin 24 cytolytic fusion protein LMB-100 (LMB-100) with or without nab-paclitaxel in treating patients with mesothelin positive solid tumors or pancreatic cancer that has come back and has spread to other places in the body. Immunotoxins, such as LMB-100, are antibodies linked to a toxic substance and may help find tumor cells that express the mesothelin protein and kill them without harming normal cells. Drugs used in chemotherapy, such as nab-paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving LMB-100 therapy with or without nab-paclitaxel may work in treating patients with mesothelin positive solid tumors or pancreatic cancer.
    Location: National Institutes of Health Clinical Center, Bethesda, Maryland

  • LMB-100 with or without Nab-Paclitaxel in Treating Patients with Malignant Mesothelioma That Cannot Be Removed by Surgery

    This phase I trial studies the side effects and best dose of anti-mesothelin-pseudomonas exotoxin 24 cytolytic fusion protein LMB-100 (LMB-100) with or without paclitaxel albumin-stabilized nanoparticle formulation (nab-paclitaxel) in treating patients with malignant mesothelioma that cannot be removed by surgery. Immunotoxins, such as LMB-100, are antibodies linked to a toxic substance and may help find tumor cells that express mesothelin and kill them without harming normal cells. Drugs used in chemotherapy, such as nab-paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. LMB-100 and nab-paclitaxel may work better in treating patients with malignant mesothelioma.
    Location: National Institutes of Health Clinical Center, Bethesda, Maryland

  • Dose Escalation and Expansion Study of GSK3359609 in Subjects With Selected Advanced Solid Tumors (INDUCE-1)

    GSK3359609 is an anti-Inducible T cell Co-Stimulator (ICOS) receptor agonist antibody intended for the treatment of cancers of different histology. This is a first-time-in-human (FTIH), open-label. multicenter study designed to investigate the safety, pharmacology, and preliminary antitumor activity in subjects with advanced or recurrent solid tumors with the aim to establish recommended dose(s) of GSK3359609 for further exploration as monotherapy and in combination with pembrolizumab or other immune therapies. The study is comprised of two primary parts, each composed of two phases: Part 1: GSK3359609 monotherapy with Part 1A as dose escalation phase and Part 1B as dose expansion phase; Part 2: GSK3359609 combination therapy with Part 2A dose escalation phase and Part 2B dose expansion phase. Each part and phase of the study includes a screening period, a treatment period, and a follow-up period. The primary objective of the study is to determine the safety, tolerability, maximum tolerated dose or the maximum administered dose of GSK3359609 alone or in combination.
    Location: Fox Chase Cancer Center, Philadelphia, Pennsylvania

  • Pembrolizumab in Treating Patients with Malignant Pleural Mesothelioma That Can Be Removed by Surgery

    This pilot clinical trial studies pembrolizumab in treating patients malignant pleural mesothelioma that can be removed by surgery. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread.
    Location: University of Chicago Comprehensive Cancer Center, Chicago, Illinois

  • Accelerated Hypofractionated Radiation Therapy Immediately before Surgery in Treating Patients with Malignant Pleural Mesothelioma

    This pilot phase 0 trial studies accelerated hypofractionated radiation therapy immediately before surgery in treating patients with malignant pleural mesothelioma (cancer in the thin layer of tissue that covers the lungs and lines the interior wall of the chest cavity). Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Hypofractionated radiation therapy is a type of radiation therapy in which the total prescribed dose of radiation is divided into fewer but larger doses as compared to conventional radiation therapy. Giving accelerated hypofractionated radiation therapy immediately before surgery may improve survival, and may also reduce side effects experienced by patients with pleural mesothelioma.
    Location: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California


1 2 Next >